Combining large data with gene technology

The combination of big data and genetic testing, though controversial, has been recombine by a biotech company and has dramatically reduced the cost of genetic testing. We can expect that the combination of Internet and biotechnology will produce more and more start-ups.

Today, in addition to preparing diapers, bottles and baby bags, expectant mothers will include genetic tests in their plans. Genetic testing can give future parents more insight into the health of their unborn baby. The process of screening for and embryo implantation in a family has changed dramatically.

Biotech company Recombine A genetic test that requires only 500 dollars, and its cost is much lower than the original level in the market. Genetic testing is a fast-growing area, with a market valuation of 25 billion dollars by 2021.

Recombine's genetic tests were screened in more than 200 different conditions to identify a couple who carried a disease-causing gene and were able to pick out an embryo in vitro fertilization. Illumina, a company based in California, also offers genetic sequencing services, a recombine competitor. But Recombine's co-founder, Alex Bisignano, said the results of their genetic tests are quicker, cheaper, and more confident, and the genome paradigm has changed, and in the past, you have to do a single test and then report to the doctor a "Yes/no" result, and now you're doing a test , you can get thousands of messages.

Recombine received a 450,000 dollar seed investment in 2012 and received 3.3 million dollars in funding from Firstmark capital this March. Recombine is headquartered in Harlem Biospace and has a laboratory in New Jersey. Harlem Biospace is a bio-tech creation space, located in New York, 36 Krypton will further open the veil of the creation of space, please look forward to!

Initially, in order to avoid the United States Drug Control Agency (FDA) intervention, recombine services only for doctors and fertility clinics, on the basis of the establishment of the face of ordinary customers of the Personal Genome Service website 23andMe. Until last fall, Recombine began to make a profit, earning 3.5 million of dollars in revenue and providing services to 10,000 couples. Next year, they plan to provide a fertility chart for researchers to study some of the complex problems of childbirth, such as recurrent miscarriage. Recombine also wants to apply his software to areas not yet developed in the marketplace, such as oncology, where DNA data can be used to predict which patients will not reject treatment.

36 Krypton will continue to focus on biotech start-ups, and more small partners are welcome to join us, if you have something to say about biotech, email to kn[at]36kr.com! []